Peripartum cardiomyopathy (PPCM) is a rare heart muscle disease that affects women during the last month of pregnancy or within five months after childbirth. The disease manifests as acute and/or chronic heart failure (CHF). In addition to standard CHF therapy, PPCM treatment includes bromocriptine, which blocks the production of anti-angiogenic 16kDa low-molecular-weight prolactin. This prolactin plays an important role in PPCM pathogenesis. Although effective treatments are available, some aspects of managing this condition remain unresolved, ranging from epidemiology to treatment duration. This article presents a clinical case report of a patient with PCMP and details the monitoring of her clinical, instrumental, and laboratory data over a 15-month period.